Table 7.
Off-Label Single-Drug Classifications for Adverse Events in the KIDS-KD Data
| Drug Classification | 2014 (N=307) | 2015 (N=436) | 2016 (N=1007) | 2017 (N=513) | 2018 (N=733) |
|---|---|---|---|---|---|
| Second generation antipsychotics | 1 (0.33) | 7 (1.61) | 421 (41.81) | 21 (4.09) | 13 (1.77) |
| Parathyroid hormones and analogues | 8 (2.61) | 58 (13.30) | 242 (24.03) | 122 (23.78) | 14 (1.91) |
| Antineoplastic agents | 2 (0.65) | 29 (6.65) | 37 (3.67) | 49 (9.55) | 148 (20.19) |
| Chemotherapy | 0 | 6 (1.38) | 8 (0.79) | 11 (2.14) | 11 (1.50) |
| Targeted therapy | 2 (0.65) | 26 (5.96) | 30 (2.98) | 49 (9.55) | 148 (20.19) |
| Immunosuppressants | 63 (20.52) | 66 (15.14) | 26 (2.58) | 43 (8.38) | 49 (6.68) |
| Direct acting antivirals | 0 | 2 (0.46) | 13 (1.29) | 23 (4.48) | 124 (16.92) |
| Hormonal contraceptives for systemic use | 43 (14.01) | 16 (3.67) | 14 (1.39) | 19 (3.70) | 9 (1.23) |
| Antiepileptics | 7 (2.28) | 16 (3.67) | 37 (3.67) | 16 (3.12) | 20 (2.73) |
| Drugs used in benign prostatic hypertrophy | 24 (7.82) | 16 (3.67) | 13 (1.29) | 9 (1.75) | 13 (1.77) |
| Antiinfectives and antiseptics, excl. Combinations | 47 (14.31) | 10 (2.29) | 0 | 4 (0.78) | 6 (0.82) |
| Antithrombotic agents | 2 (0.65) | 11 (2.52) | 21 (2.09) | 23 (4.48) | 4 (0.55) |
| Antidepressants | 5 (1.63) | 7 (1.61) | 7 (0.70) | 3 (0.58) | 14 (1.91) |
Note: Values are reported as n (%).
Abbreviation: KIDS-KD, the Korea Institute of Drug Safety & Risk Management (Ministry of Food and Drug Safety)-Korea Adverse Event Reporting System database.